Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo

PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells

(2014) Margaret A. Park et al.   Autophagy

Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy

(2012) Dariusz Pytel et al.   Anti-Cancer Agents in Medicinal Chemistry

Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review

(2010) Adrian Yun-San Yip et al.   ANTI-CANCER DRUGS

Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation

(2010) Margaret A. Park et al.   CANCER BIOLOGY & THERAPY

Inhibition of MCL-1 enhances Lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy

(2010) Aditi Pandya Martin et al.   CANCER BIOLOGY & THERAPY

The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells

(2010) Jingxuan Pan et al.   CANCER LETTERS

Radiosensitization of Epidermal Growth Factor Receptor/HER2-Positive Pancreatic Cancer Is Mediated by Inhibition of Akt Independent of Ras Mutational Status

(2010) R. J. Kimple et al.   CLINICAL CANCER RESEARCH

Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor—2 tyrosine kinases used in the treatment of breast cancer

(2010) Amye J. Tevaarwerk et al.   CLINICAL THERAPEUTICS

Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition

(2010) G. Zoppoli et al.   CURRENT CANCER DRUG TARGETS

Selective Cyclin-Dependent Kinase Inhibitors Discriminating between Cell Cycle and Transcriptional Kinases

(2009) Józefa Węsierska-Gądek et al.   Annals of the New York Academy of Sciences

Mitochondrial dysfunction resulting from loss of cytochrome c impairs radiation-induced bystander effect

(2009) G Yang et al.   BRITISH JOURNAL OF CANCER

Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells

(2009) S. Benavente et al.   CLINICAL CANCER RESEARCH

Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy

(2009) M. H. Kang et al.   CLINICAL CANCER RESEARCH

Small-molecule inhibitors of the human epidermal receptor family

(2009) Corey A Carter et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

ABT-737 Synergizes with Chemotherapy to Kill Head and Neck Squamous Cell Carcinoma Cells via a Noxa-Mediated Pathway

(2009) R. Li et al.   MOLECULAR PHARMACOLOGY

Is the focus moving toward a combination of targeted drugs?

(2008) Steven Grant   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Met and c-Src Cooperate to Compensate for Loss of Epidermal Growth Factor Receptor Kinase Activity in Breast Cancer Cells

(2008) K. L. Mueller et al.   CANCER RESEARCH

Gefitinib for the treatment of non-small-cell lung cancer

(2008) Toyoaki Hida et al.   Expert Review of Anticancer Therapy

Multiple Cyclin Kinase Inhibitors Promote Bile Acid-induced Apoptosis and Autophagy in Primary Hepatocytes via p53-CD95-dependent Signaling

(2008) Guo Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy

(2008) Asfar S. Azmi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Cross-Talk Between the ErbB/HER Family and the Type I Insulin-Like Growth Factor Receptor Signaling Pathway in Breast Cancer

(2008) Quanri Jin et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95

(2008) M. A. Park et al.   MOLECULAR CANCER THERAPEUTICS

OSU-03012 Stimulates PKR-Like Endoplasmic Reticulum-Dependent Increases in 70-kDa Heat Shock Protein Expression, Attenuating Its Lethal Actions in Transformed Cells

(2008) M. A. Park et al.   MOLECULAR PHARMACOLOGY

Lapatinib Resistance in HCT116 Cells Is Mediated by Elevated MCL-1 Expression and Decreased BAK Activation and Not by ERBB Receptor Kinase Mutation

(2008) A. P. Martin et al.   MOLECULAR PHARMACOLOGY